This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Sepsis

Ataxia telangienctasia mutated (ATM); DNA damage response

Mouse studies suggest anthracyclines could be used to treat sepsis by activating the DNA damage response. In a mouse model of severe sepsis, several anthracyclines increased survival compared with saline but did not decrease bacterial load. In the model, deletion of the DNA damage response gene Atm or disruption of autophagy in the lung eliminated the protective effects of anthracyclines. Next steps include conducting a clinical trial next year with epirubicin in patients with sepsis and testing anthracyclines in animal models of additional inflammatory diseases.
Epirubicin is a generic topoisomerase II (TOP2) inhibitor.

SciBX 6(47); doi:10.1038/scibx.2013.1356
Published online Dec. 12, 2013

Patent application filed; unavailable for licensing

Figueiredo, N. et al. Immunity; published online Oct. 31, 2013;
doi:10.1016/j.immuni.2013.08.039
Contact: Luis F. Moita, University of Lisbon, Lisbon, Portugal
e-mail:
lmoita@fm.ul.pt